Get Full Government Meeting Transcripts, Videos, & Alerts Forever!
House subcommittee hears bipartisan concerns over U.S. dependence on foreign drug supply chains
Summary
A House Energy and Commerce subcommittee hearing spotlighted risks in the U.S. pharmaceutical supply chain, with witnesses and members urging long-term federal purchasing, inspection capacity and targeted incentives to rebuild domestic production of APIs, key starting materials and finished medicines.
A House Energy and Commerce Subcommittee on Health hearing on June 25 examined vulnerabilities in the U.S. drug supply chain and possible fixes, with lawmakers and industry witnesses warning that reliance on foreign manufacturers — particularly upstream suppliers in China and India — threatens public health and national security.
The session opened with Chairman Buddy Carter saying, “The United States should never be dependent on the Chinese Communist Party for the antibiotics and essential medicines,” and continued with testimony from domestic manufacturers, trade groups and standard-setting bodies about concentrated production of active pharmaceutical ingredients (APIs) and key starting materials (KSMs), dwindling U.S. capacity, and the practical steps needed to restore resilience.
Why it matters: witnesses described a supply chain that is “longer, more fragmented, and more opaque” and identified a set of interlocking problems — low prices for many generics, concentrated upstream production of KSMs, slow permitting and long build…
Already have an account? Log in
Subscribe to keep reading
Unlock the rest of this article — and every article on Citizen Portal.
- Unlimited articles
- AI-powered breakdowns of topics, speakers, decisions, and budgets
- Instant alerts when your location has a new meeting
- Follow topics and more locations
- 1,000 AI Insights / month, plus AI Chat
